Target Validation for Genetic Targets – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Genetic target validation is a critical step in the drug discovery process, confirming the potential of a target candidate as a therapy. In terms of key innovation areas, genetic target validation is considered a medium-impact innovation in the near term due to the availability of multiple products and solutions in this field.
Patent analysis shows a growing trend in genetic target validation, although the pace is slower compared to other innovations. Interestingly, universities and research institutions dominate the patent landscape, accounting for close to 50% of all patents filed in recent years. China-based companies also show dominance in patent trends, with 60% of all patents filed at the China patent office.
Competition in the field is focused on genomic analysis and organ/tissue-based techniques, with more companies now exploring genetic manipulation-based techniques. Leading patent filers include BGI Biotech and Illumina, with patents in genomic analysis and high throughput screening methods. Chinese companies like Biocytogen, GemPharma, and Surexam have technology cycle times lower than the industry average. Among big pharma companies, Alnylam, Regeneron, Vertex, and Johnson & Johnson have patents related to target validation.
In the startup ecosystem, companies like Emulate, Bi/Ond Solutions, and Insphero are leading the way in developing organoid/organ-on-a-chip models for target validation studies. Over 40 startups are active in this space, with Leapfrog Bio being the latest entry with a patent on Crispr screens for oncology targets. Startups are particularly focused on organ/tissue-based models and genetic manipulation techniques.
More than 200 universities are involved in genetic target validation research, with Stanford University and the Chinese Academy of Sciences leading the way.
In terms of deals related to genetic target validation, there have been 14,172 deals totaling US$11.4 billion. The United States has been a major player in this space, with a significant Grants deal worth $7.8 billion. The highest deal volume was seen in 2023 with 3,569 deals, while the highest deal value was recorded in 2020 at $4.1 billion. The slight decline in deals in 2021, followed by a modest increase in 2022, may indicate market adjustments and strategic consolidations. The United States leads in terms of deal amount and volume since 2020.

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

1. Target validation for genetic targets report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications.

2. Big pharma companies like BGI biotech dominate the patent activity in Target Validation for genetic targets with a dip in new companies filing patents in recent years.

3. Competitive intelligence shows that BGI biotech and illumina are among the leaders with strong innovation portfolios in Target Validation for genetic targets.

4. Startups like surexam and Emulate are leading in terms of innovation impact and focus in the Target Validation for genetic targets.

Reasons to Buy

Gain a deeper understanding of the critical role of Target validation in drug discovery. This report provides comprehensive insights into the various methods used for validating genetic targets, including genetic knockout studies, RNA interference, and small molecule inhibitors. It highlights the challenges and limitations of target validation while emphasizing the importance of robust experimental design and data interpretation. With valuable data on the latest trends and best practices, this report equips researchers and decision-makers with the tools needed to increase the success rate of developing effective therapies for a range of diseases. Stay ahead of the curve and make informed decisions in the fast-evolving field of genetic target validation.

BGI Biotech
Illumina
Biocytogen
Regeneron
Sekisui
Pacific Biosciences
Qiagen
Bio-rad
Vertax pharma
Agilent
Mesoblast
Organovo
thermo fisher
DNA chips
Celemics
Bioarctic
Hitgen
JnJ

Table of Contents

Table of Contents

1. Innovation Insights

1.1 Innovation radar

1.2 Innovation s-curve

1.3 Innovation deep dive

1.4 Innovation deep dive – trending indications

1.5 Top companies Based on temporal indicators

2. Competitive Insights

2.1 Key innovation leaders – big pharma

2.2.Key innovators – startups and small biotech

2.3 Key innovations – Universities and research institutions

2.4 Most cited patents

2.5 Insights from AI hub

3.Market Insights

3.1 Deals

3.2. Key Acquirers

3.3 Deal type distribution

3.4 Geographical distribution

Target Validation for Genetic Targets – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals standard reports
Currency USD
$2,499

Can be used by individual purchaser only

$7,497

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Target Validation for Genetic Targets – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Target Validation for Genetic Targets – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals in real time.

  • Access a live Target Validation for Genetic Targets – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.